Cell Therapy Developers Roadmap
5 Analytical Pitfalls To Avoid In Cell Therapy Development
Spot the exact point in your program where these failures are easiest to miss, and cheapest to fix, before a reviewer finds them for you.
See how these five failures compound. A weak CQA in Mistake #2 is what makes Mistake #3's comparability collapse and Mistake #5's traceability gap so hard to trace back.
See what it actually costs to get this wrong, in real cases with real timelines and dollars attached, not a hypothetical.
What You Receive
A few questions to check your own analytical strategy against. Like whether your CQAs answer what a reviewer will ask, or whether you could trace one patient's product in a single query.
Examples of how each mistake shows up in practice. Sourced cases and a few firsthand ones.
A starting point for each mistake. Somewhere concrete to start the conversation with your team.
What's Inside
Day 1: Your potency assay passes every internal check. Find out why that's not the same as answering the question a reviewer will actually ask.
Day 2: A vague CQA doesn't get caught at the bench. It gets caught in review, months after the decision that created it.
Day 3: A manufacturing change made for good operational reasons can be the exact thing that stalls patient dosing. Here's the gap most teams miss.
Day 4: Regulatory flexibility loosened more than most sponsors realize, and tightened in a place most sponsors aren't watching.
Day 5: One traceability gap, in a program otherwise built on strong science, is enough to stall a submission.
The first mistake of 5 Analytical Pitfalls is on its way to your inbox.
Check your inbox for an email with the details on the Cell Therapy Developers Roadmap.
If you have any questions along the way, just hit reply. I'm happy to help.
P.S. If you don't find the email in your inbox in the next couple of minutes, please check your spam folder.